Pfizer has started construction on a new consumer products production facility in Suzhou, China, which will involve an investment of around $95m.
The new facility is being developed to increase production capacity to meet the growing demand for its healthcare brands in China and the Asia-Pacific region.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Pfizer Consumer Healthcare Asia-Pacific and Europe, Middle East and Africa regional president Andy Schmeltz said: "Asia-Pacific is a large and rapidly growing region for Pfizer Consumer Healthcare and our new plant in Suzhou will give us the production capacity we need to meet increasing demand for our brands, particularly in China."
The new facility will be mainly used for the production of Caltrate dietary supplements and Centrum multivitamins and will also support production of additional products in the future.
In addition, the company intends to house a research and development facility on the new site to support innovation in the region.
Pfizer Consumer Healthcare North Asia regional general manager Keith Choy said: "We are pleased to build on the strong foundation we have in Suzhou, where we have produced consumer healthcare and prescription products for more than 20 years."
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHaving began production in 1994, Pfizer Suzhou facility produces Centrum multivitamins, Caltrate dietary supplements, Robitussin cough and cold products, antibiotics, as well as other prescription and over-the-counter products.
Products produced in the facility will be distributed to multiple countries in the Asia Pacific region, including China.
